Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
James R. KasingerGeneral Counsel and Secretary | Crispr TherapeuticsCRSP | Open-market sale10b5-1 plan | 09/22 | 09/24 | 10,400 sh | $60.24 | $626,459.6 | −9.9% |
Naimish PatelChief Medical Officer | Crispr TherapeuticsCRSP | Open-market sale | 05/29 | 06/01 | 3,786 sh | $55.62 | $210,577.32 | −16.4% |
Crispr TherapeuticsCRSP | Open-market sale | 03/23 | 03/24 | 10,020 sh | $46.78 | $468,735.6 | −3.8% | |
James R. KasingerGeneral Counsel and Secretary | Crispr TherapeuticsCRSP | Open-market sale | 03/23 | 03/24 | 3,182 sh | $46.78 | $148,853.96 | −3.3% |
Raju PrasadCFO | Crispr TherapeuticsCRSP | Open-market sale | 03/23 | 03/24 | 3,708 sh | $46.78 | $173,460.24 | −19.2% |
Crispr TherapeuticsCRSP | Open-market sale | 03/16 | 03/17 | 10,349 sh | $48.26 | $499,442.74 | −4.0% | |
James R. KasingerGeneral Counsel and Secretary | Crispr TherapeuticsCRSP | Open-market sale | 03/16 | 03/17 | 3,450 sh | $48.26 | $166,497 | −3.6% |
Crispr TherapeuticsCRSP | Open-market sale | 03/16 | 03/17 | 9,869 sh2 trades | $48.26avg. | $476,277.94 | −41.7% | |
Naimish PatelChief Medical Officer | Crispr TherapeuticsCRSP | Open-market sale | 03/16 | 03/17 | 3,150 sh | $48.26 | $152,019 | −19.3% |
Crispr TherapeuticsCRSP | Open-market sale | 03/11 | 03/12 | 9,798 sh | $52.80 | $517,334.4 | −4.0% | |
James R. KasingerGeneral Counsel and Secretary | Crispr TherapeuticsCRSP | Open-market sale | 03/11 | 03/12 | 2,800 sh | $52.80 | $147,840 | −3.1% |
Crispr TherapeuticsCRSP | Open-market sale | 02/19 | 02/20 | 6,967 sh | $52.58 | $366,324.86 | −3.0% | |
James R. KasingerGeneral Counsel and Secretary | Crispr TherapeuticsCRSP | Open-market sale | 02/19 | 02/20 | 2,112 sh | $52.58 | $111,048.96 | −2.4% |
Naimish PatelChief Medical Officer | Crispr TherapeuticsCRSP | Open-market buy | 25/04/03 | 01/27 | 1,508 sh | $32.96 | $49,703.68 | No record |
Raju PrasadCFO | Crispr TherapeuticsCRSP | Open-market sale10b5-1 plan | 01/22 | 01/26 | 34,972 sh | $60.19 | $2,104,964.68 | −83.8% |
Crispr TherapeuticsCRSP | Open-market sale10b5-1 plan | 01/20–01/22 | 01/22 | 90,000 sh3 trades | $57.40avg. | $5,166,297.83 | −40.1% | |
Crispr TherapeuticsCRSP | Open-market sale10b5-1 plan | 01/06 | 01/08 | 29,700 sh3 trades | $60.16avg. | $1,786,618.17 | −81.4% | |
Crispr TherapeuticsCRSP | Open-market sale10b5-1 plan | 25/12/22 | 25/12/23 | 10,000 sh3 trades | $55.95avg. | $559,520.56 | −59.6% | |
Crispr TherapeuticsCRSP | Open-market sale | 25/10/17 | 25/10/20 | 50,895 sh | $67.91 | $3,456,279.45 | −16.7% | |
Crispr TherapeuticsCRSP | Open-market sale | 25/10/14 | 25/10/15 | 4,242 sh | $66.60 | $282,517.2 | −2.0% |
